StockNews.com lowered shares of Simulations Plus (NASDAQ:SLP - Free Report) from a hold rating to a sell rating in a research report released on Monday morning.
A number of other analysts have also weighed in on the company. KeyCorp increased their target price on Simulations Plus from $35.00 to $37.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. William Blair reissued an "outperform" rating on shares of Simulations Plus in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $50.00.
Get Our Latest Research Report on Simulations Plus
Simulations Plus Trading Up 1.5 %
SLP traded up $0.49 during trading hours on Monday, hitting $32.69. The company's stock had a trading volume of 336,728 shares, compared to its average volume of 193,468. Simulations Plus has a 12 month low of $23.01 and a 12 month high of $51.22. The business's 50-day moving average price is $28.55 and its 200-day moving average price is $30.09. The stock has a market cap of $657.43 million, a price-to-earnings ratio of 81.73 and a beta of 1.13.
Simulations Plus (NASDAQ:SLP - Get Free Report) last released its quarterly earnings results on Thursday, April 3rd. The technology company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.25 by $0.06. The company had revenue of $22.43 million during the quarter, compared to analyst estimates of $21.93 million. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The firm's revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the business posted $0.20 earnings per share. On average, analysts forecast that Simulations Plus will post 1.09 earnings per share for the current year.
Insider Activity
In other news, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the transaction, the director now directly owns 3,402,584 shares of the company's stock, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 19.40% of the company's stock.
Hedge Funds Weigh In On Simulations Plus
A number of large investors have recently added to or reduced their stakes in the company. Fifth Third Bancorp raised its stake in shares of Simulations Plus by 33.8% during the 1st quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company's stock worth $36,000 after acquiring an additional 375 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Simulations Plus by 4.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,103 shares of the technology company's stock valued at $254,000 after purchasing an additional 380 shares during the last quarter. Jones Financial Companies Lllp grew its stake in Simulations Plus by 53.6% during the 4th quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company's stock worth $34,000 after buying an additional 427 shares during the last quarter. Pitcairn Co. increased its position in Simulations Plus by 10.8% during the 4th quarter. Pitcairn Co. now owns 7,310 shares of the technology company's stock valued at $204,000 after buying an additional 711 shares in the last quarter. Finally, US Bancorp DE raised its stake in Simulations Plus by 14.3% in the fourth quarter. US Bancorp DE now owns 5,687 shares of the technology company's stock valued at $159,000 after buying an additional 713 shares during the last quarter. 78.08% of the stock is currently owned by institutional investors.
About Simulations Plus
(
Get Free Report)
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Featured Articles
Before you consider Simulations Plus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Simulations Plus wasn't on the list.
While Simulations Plus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
